** Analysts at Jefferies see New Zealand's Fisher & Paykel Healthcare FPH.NZ mitigating impact of 25% U.S. tariffs on Mexican imports
** Brokerage upgrades the medical equipment maker to "buy" from "hold", raises price target to NZ$39.40 from NZ$35.25
** "FPH's New Zealand-manufactured products already FDA approved, the option to substitute Mexican with NZ imports is only limited by re-routing and freight lead times," Jefferies says
** Adds that FPH's three months of inventory available in the U.S. and potential to increase prices will help further moderate the impact of tariffs in FY26
** Two of 12 analysts rate the stock "buy", seven "hold" and three "sell" or lower; their median PT is NZ$37.00 – LSEG data
** Stock closed at NZ$34.5 on Tuesday, down 10.2% YTD
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.